The consortium is conducting a multi-phase, multinational, multicenter, observational study.
The study is expected to run over 5 years in 12 African countries and planned to generate a cohort of 4,000 Parkinson's disease patients and 4,000 matched Controls. All cases and controls will be recruited using a unified clinical and genotyping protocol.
The cohort will be screened for known pathogenic Parkinson's disease variants and subjected to genome-wide analysis. The findings will be compared with results from European populations. In addition, data will be compiled with cohorts from other ethnic backgrounds within the Global Parkinson's Genetics Program (GP2) to help fine-mapping Parkinson's disease loci in other populations and plan future studies.